LVGN-5596

N/A

Report date: 2022/01/21 15:33:39

Base Information

Drug NameLVGN-5596

Drug Alias NameLVGN-5596

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionCD276 antigen inhibitorsTumor necrosis factor receptor superfamily member 5 inhibitors

TargetsCD276 antigenTumor necrosis factor receptor superfamily member 5

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesLijin Biotechnology (Shanghai) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesLijin Biotechnology (Shanghai) Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A